- Home
- FLOC vs XERS Comparison
FLOC vs XERS Comparison
Compare FLOC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLOC | XERS |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | United States | United States |
| Employees | 1281 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.8M | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FLOC | XERS |
|---|---|---|
| Price | $27.35 | $6.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $28.50 | $10.83 |
| AVG Volume (30 Days) | 588.4K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $22.92 | $34.37 |
| Revenue Next Year | $8.59 | $22.86 |
| P/E Ratio | ★ $16.57 | $638.48 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $14.03 | $4.30 |
| 52 Week High | $28.26 | $10.08 |
Technical Indicators
Market Signals| Indicator | FLOC | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 64.93 | 49.57 |
| Support Level | $14.96 | $5.79 |
| Resistance Level | N/A | $6.41 |
| Average True Range (ATR) | 1.08 | 0.32 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 81.76 | 28.51 |
Price Performance
Historical ComparisonAbout FLOC Flowco Holdings Inc.
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.